DSM PHARMA SOLUTIONS
The science behind cannabinoids, like cannabidiol (CBD), is growing rapidly – with research demonstrating the potential of these molecules to support a wide range of health areas that could benefit patients with conditions including CNS (central nervous system) diseases,1 pain disorders,2 cancer3 and more. This is creating a myriad of opportunities for innovation across the pharmaceutical industry and inspiring the development of bespoke drug products that will support global patient health.
Together, DSM and Brains Bioceutical have created an innovation platform to enable agile, early drug development and help our customers realize the full therapeutic potential of bespoke cannabinoid-based pharmaceuticals. We have the core competencies, combined with a deep understanding of patient and customer needs, to help brands enter the cannabinoid market with confidence and expand treatment options for patients worldwide.
Download our NEW brochure to unlock the potential of customized cannabinoid-based pharmaceuticals. Learn more about how dsm-firmenich and Brains Bioceutical together as your end-to-end partner can help you enter the market with confidence.
It is an exciting time for pharmaceutical researchers and developers with 200+ clinical trials exploring the therapeutic capacity of CBD and an increasing bank of evidence demonstrating the promising potential of the molecule.
Download our whitepaper to explore the latest science behind CBD and discover your next opportunity in early-stage drug development.
This whitepaper explores the challenges surrounding the oral bioavailability of CBD and the benefits of using lipid-based systems in your formulation. Unlock novel opportunities in the CBD space.
Watch our latest webinar held in partnership with Manufacturing Chemist and join Professor José Alexandre de Souza Crippa, Department of Neurosciences and Behaviour, University of São Paulo, Brazil, and Dr Mariana Coelho, Clinical Project Scientist at DSM, as they discuss the latest science and promising research into whether cannabidiol is a potential therapy to treat patients suffering from mental health conditions.
CBD is set to disrupt the dietary supplement category, driven by strong consumer interest in the ingredient’s possible benefits for immunity, stress, mood, sleep and more. Learn about our CBD offering for the nutrition market and how we’re supporting customers develop health benefit-driven products – from concept to consumer – with market-ready and premix solutions.
Learn about the latest in cannabidiol (CBD) early-stage drug development from Terry O’Regan, President Brains Bioceutical, and Alexandru Zabara, Innovation Manager Pharma at DSM.
Get an expert view on how to unlock cannabinoid therapeutic innovation by advancing the scientific landscape, as well as approaches to addressing the challenge of CBD bioavailability: modulating physical properties of selected formulations in order to enhance in-vitro bioaccessibility and in-vivo pharmacokinetic performance.
Get in touch with a DSM Pharma specialist or find contacts around the world to suit your needs.
At DSM we love to connect with other humans.
Follow us on any of the channels below.